High Tower Advisors, LLC Fennec Pharmaceuticals Inc. Transaction History
High Tower Advisors, LLC
- $76.8 Billion
- Q2 2025
A detailed history of High Tower Advisors, LLC transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 15,000 shares of FENC stock, worth $120,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000Holding current value
$120,000% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FENC
# of Institutions
83Shares Held
14.2MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$32.6 Million0.98% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$19.3 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.23MShares$17.9 Million12.03% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$9.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA967KShares$7.74 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $209M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...